The following primary antibodies were used: rabbit polyclonal anti-human NSun2 (1:1,000; Meta) (Frye & Watt, 2006 (link)), rabbit polyclonal CUK-1079-A anti-mouse NSun2 (1:1,000; Covalab) (Blanco et al, 2011 (link)), mouse monoclonal anti-NMP1 (1:500; Sigma, B0556, clone FC82291), mouse monoclonal anti-angiogenin (1:200; Abcam, ab10600, clone 14017.7), goat polyclonal anti-eIF4AI (1:200; N-19) (Santa Cruz, sc-14211), goat polyclonal anti-4ET (1:200; E-18) (Santa Cruz, sc-13454), goat polyclonal anti-SK1 (1:200; A-13) (Santa Cruz, sc-17991), goat polyclonal anti-eIF3η (1:200; A-20) (Santa Cruz, sc-16378), rabbit polyclonal anti-cleaved caspase-3 (1:100; Cell Signaling, #9664), mouse anti-PSD95 (1:200; Thermo Scientific), rabbit antisynapsin (1:1,000; Synaptic Systems), mouse anti-GFAP (1:200; Millipore), rabbit anti-Tbr1 (1:500, Abcam), rabbit anti-Dcx (1:100, Abcam).
NaAsO2 was used at 200 μM (Sigma). The angiogenin small-molecule inhibitor N65828 (8-amino-5-(4′-hydroxybiphenyl-4-ylazo)naphthalene-2-sulphonate) was obtained from the National Cancer Institute (http://dtp.cancer.gov ). NAC was purchased from Sigma and O-propargyl-puromycin (OP-puromycin) from Medchem Source LLP.
NaAsO2 was used at 200 μM (Sigma). The angiogenin small-molecule inhibitor N65828 (8-amino-5-(4′-hydroxybiphenyl-4-ylazo)naphthalene-2-sulphonate) was obtained from the National Cancer Institute (
Free full text: Click here
